A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

NCT03468556 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG: SNP-610
DRUG: Placebo Oral Tablet

Sponsor

Sinew Pharma Inc.